Recent Developments in Pediatric Community-Acquired Pneumonia

Current Infectious Disease Reports

Volumn 18, Issue 5, 2016, Pages

  McCulloh, Russell J ^a,b   Patel, Karisma ^a  

^a CHILDREN S MERCY HOSPITAL   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Community acquired pneumonia; Molecular diagnostics; Pediatric; Pneumococcus; Viral pneumonia

Indexed keywords

AMPICILLIN; AZITHROMYCIN; BETA LACTAM; CORTICOSTEROID; LEVOFLOXACIN; MACROLIDE; PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BLOOD CULTURE; BURKHOLDERIA PSEUDOMALLEI; CHLAMYDIA PNEUMONIAE; COMMUNITY ACQUIRED PNEUMONIA; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; DRUG EFFICACY; ECHOGRAPHY; EPIDEMIOLOGICAL DATA; HAEMOPHILUS INFLUENZAE; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HUMAN; KLEBSIELLA PNEUMONIAE; MONOTHERAPY; MYCOPLASMA PNEUMONIAE; NONHUMAN; PATIENT CARE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); THORAX RADIOGRAPHY; VACCINATION;

EID: 84961249552     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-016-0521-1     Document Type: Review

References (89)

1. World Health Organization. Pneumonia. Fact sheet No. 331. 2014.
2. Lee GE et al. National hospitalization trends for pediatric pneumonia and associated complications. Pediatrics. 2010;126(2):204–13.
3. Keitel K et al. Observed costs and health care use of children in a prospective cohort study on community-acquired pneumonia in Geneva. Switzerland Swiss Med Wkly. 2014;144:w13925.
4. Jain S et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med. 2015;372(9):835–45. This article reports on the results of the largest epidemiological study of pediatric CAP in children to date. Additionally, the use of multiple pathogen detection methods provides unprecedented insight into causative etiologies for CAP, particularly viral causes.
5. Cantais A et al. Epidemiology and microbiological investigations of community-acquired pneumonia in children admitted at the emergency department of a university hospital. J Clin Virol. 2014;60(4):402–7.
6. Self WH, et al. Respiratory viral detection in children and adults: comparing asymptomatic controls and patients with community-acquired pneumonia. J Infect Dis. 2015.
7. Rhedin S et al. Respiratory viruses associated with community-acquired pneumonia in children: matched case-control study. Thorax. 2015;70(9):847–53.
8. Wang M et al. Incidence of viral infection detected by PCR and real-time PCR in childhood community-acquired pneumonia: a meta-analysis. Respirology. 2015;20(3):405–12.
9. Goyet S et al. Etiologies and resistance profiles of bacterial community-acquired pneumonia in Cambodian and neighboring countries’ health care settings: a systematic review (1995 to 2012). PLoS One. 2014;9(3), e89637.
10. Chen K et al. The aetiology of community associated pneumonia in children in Nanjing, China and aetiological patterns associated with age and season. BMC Public Health. 2015;15:113.
11. Huong Ple T et al. First report on prevalence and risk factors of severe atypical pneumonia in Vietnamese children aged 1–15 years. BMC Public Health. 2014;14:1304.
12. Medjo B et al. Mycoplasma pneumoniae as a causative agent of community-acquired pneumonia in children: clinical features and laboratory diagnosis. Ital J Pediatr. 2014;40:104.
13. Ma YJ, et al. Clinical and epidemiological characteristics in children with community-acquired mycoplasma pneumonia in Taiwan: a nationwide surveillance. J Microbiol Immunol Infect. 2014; 632–8.
14. Sun H et al. Epidemiology and clinical profiles of Mycoplasma pneumoniae infection in hospitalized infants younger than one year. Respir Med. 2015;109(6):751–7.
15. Esposito S et al. Enterovirus D68-associated community-acquired pneumonia in children living in Milan. Italy J Clin Virol. 2015;68:94–6.
16. Imamura T, Oshitani H. Global reemergence of enterovirus D68 as an important pathogen for acute respiratory infections. Rev Med Virol. 2015;25(2):102–14.
17. Bragstad K et al. High frequency of enterovirus D68 in children hospitalised with respiratory illness in Norway, autumn 2014. Influenza Other Respir Viruses. 2015;9(2):59–63.
18. Schuster JE et al. Severe enterovirus 68 respiratory illness in children requiring intensive care management. J Clin Virol. 2015;70:77–82.
19. Deva A et al. Pneumococcal infections at a rural tertiary care hospital: a seven year study on isolation rate, clinical spectrum and antibiogram. J Clin Diagn Res. 2014;8(2):50–2.
20. Diaz MH et al. Molecular detection and characterization of Mycoplasma pneumoniae among patients hospitalized with community-acquired pneumonia in the United States. Open Forum Infect Dis. 2015;2(3):ofv106.
21. Meyer Sauteur PM et al. Survey of macrolide-resistant Mycoplasma pneumoniae in children with community-acquired pneumonia in Switzerland. Swiss Med Wkly. 2014;144:w14041.
22. Tregnaghi MW et al. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial. PLoS Med. 2014;11(6), e1001657.
23. Abrao WM et al. Impact of the antipneumococcal conjugate vaccine on the occurrence of infectious respiratory diseases and hospitalization rates in children. Rev Soc Bras Med Trop. 2015;48(1):44–9.
24. Angoulvant F et al. Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children. Clin Infect Dis. 2014;58(7):918–24.
25. Greenberg D et al. Impact of PCV7/PCV13 introduction on community-acquired alveolar pneumonia in children <5 years. Vaccine. 2015;33(36):4623–9.
26. Naito S, et al. The impact of heptavalent pneumococcal conjugate vaccine on the incidence of childhood community-acquired pneumonia and bacteriologically confirmed pneumococcal pneumonia in Japan. Epidemiol Infect. 2015; 1–13.
27. Pirez MC et al. Changes in hospitalizations for pneumonia after universal vaccination with pneumococcal conjugate vaccines 7/13 valent and Haemophilus influenzae type b conjugate vaccine in a pediatric referral hospital in Uruguay. Pediatr Infect Dis J. 2014;33(7):753–9.
28. De Schutter I et al. Pneumococcal aetiology and serotype distribution in paediatric community-acquired pneumonia. PLoS One. 2014;9(2), e89013.
29. Damm O et al. Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany. Eur J Health Econ. 2015;16(5):471–88. This article provides country-level data regarding the potential benefit of widespread influenza vaccination, including expected numbers of averted cases of viral pneumonia. Such information is important for clinicians, public health officials, and third-party payers to consider in decisions of vaccine administration and policy.
30. Ahn A, et al. Secondhand smoke exposure and illness severity among children hospitalized with pneumonia. J Pediatr. 2015; 869–74.
31. Azab SF et al. Impact of the socioeconomic status on the severity and outcome of community-acquired pneumonia among Egyptian children: a cohort study. Infect Dis Poverty. 2014;3:14.
32. Elemraid MA et al. Risk factors for the development of pleural empyema in children. Pediatr Pulmonol. 2015;50(7):721–6.
33. Greenberg D et al. Increased risk for respiratory syncytial virus-associated, community-acquired alveolar pneumonia in infants born at 31–36 weeks of gestation. Pediatr Infect Dis J. 2014;33(4):381–6.
34. Zidan HE, Elbehedy RM, Azab SF. IL6-174 G/C gene polymorphism and its relation to serum IL6 in Egyptian children with community-acquired pneumonia. Cytokine. 2014;67(2):60–4.
35. Emery DP et al. The impact of primary care on emergency department presentation and hospital admission with pneumonia: a case-control study of preschool-aged children. NPJ Prim Care Respir Med. 2015;25:14113.
36. Wilson KM et al. Hospitalization for community-acquired pneumonia in children: effect of an asthma codiagnosis. Hosp Pediatr. 2015;5(8):415–22.
37. Coon ER, Maloney CG, Shen MW. Antibiotic and diagnostic discordance between ED physicians and hospitalists for pediatric respiratory illness. Hosp Pediatr. 2015;5(3):111–8.
38. Lai EM et al. Should all children admitted with community acquired pneumonia have blood cultures taken? Indian J Pediatr. 2015;82(5):439–44.
39. Parikh K, Davis AB, Pavuluri P. Do we need this blood culture? Hosp Pediatr. 2014;4(2):78–84.
40. Iroh Tam PY et al. Blood culture in evaluation of pediatric community-acquired pneumonia: a systematic review and meta-analysis. Hosp Pediatr. 2015;5(6):324–36.
41. McCulloh RJ et al. Evaluating the use of blood cultures in the management of children hospitalized for community-acquired pneumonia. PLoS One. 2015;10(2), e0117462.
42. Schulert GS, Hain PD, Williams DJ. Utilization of viral molecular diagnostics among children hospitalized with community acquired pneumonia. Hosp Pediatr. 2014;4(6):372–6.
43. McCulloh RJ et al. Potential utility of multiplex amplification respiratory viral panel testing in the management of acute respiratory infection in children: a retrospective analysis. Journal of the Pediatric Infectious Diseases Society. 2014;3(2):146–53.
44. Pernica JM et al. Real-time polymerase chain reaction for microbiological diagnosis of parapneumonic effusions in Canadian children. Can J Infect Dis Med Microbiol. 2014;25(3):151–4.
45. Aizawa Y et al. Clinical utility of loop-mediated isothermal amplification for rapid diagnosis of Mycoplasma pneumoniae in children. J Med Microbiol. 2014;63(Pt 2):248–51.
46. Alcoba G et al. Proadrenomedullin and copeptin in pediatric pneumonia: a prospective diagnostic accuracy study. BMC Infect Dis. 2015;15(1):347.
47. Elemraid MA et al. Utility of inflammatory markers in predicting the aetiology of pneumonia in children. Diagn Microbiol Infect Dis. 2014;79(4):458–62.
48. Williams DJ et al. Association of white blood cell count and C-reactive protein with outcomes in children hospitalized for community-acquired pneumonia. Pediatr Infect Dis J. 2015;34(7):792–3.
49. Fonseca TS, et al. Pleural effusion increases serum procalcitonin values in children with community-acquired pneumonia. Pediatr Infect Dis J. 2015; 914–5.
50. Hoshina T et al. The utility of biomarkers in differentiating bacterial from non-bacterial lower respiratory tract infection in hospitalized children: difference of the diagnostic performance between acute pneumonia and bronchitis. J Infect Chemother. 2014;20(10):616–20.
51. Wrotek A, Jackowska T, Pawlik K. Soluble urokinase plasminogen activator receptor: an indicator of pneumonia severity in children. Adv Exp Med Biol. 2015;835:1–7.
52. Wrotek A, Jackowska T, Pawlik K. Sodium and copeptin levels in children with community acquired pneumonia. Adv Exp Med Biol. 2015;835:31–6.
53. Esposito S et al. Performance of lung ultrasonography in children with community-acquired pneumonia. Ital J Pediatr. 2014;40:37.
54. Urbankowska E., et al. Lung ultrasound in the diagnosis and monitoring of community acquired pneumonia in children. Respir Med. 2015; 1207–12.
55. Reali F et al. Can lung ultrasound replace chest radiography for the diagnosis of pneumonia in hospitalized children? Respiration. 2014;88(2):112–5.
56. Ho MC et al. Usefulness of lung ultrasound in the diagnosis of community-acquired pneumonia in children. Pediatr Neonatol. 2015;56(1):40–5.
57. Lai SH, Wong KS, Liao SL. Value of lung ultrasonography in the diagnosis and outcome prediction of pediatric community-acquired pneumonia with necrotizing change. PLoS One. 2015;10(6), e0130082.
58. Bradley JS et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011;53(7):e25–76.
59. Selby A, Pettit K, Brown N. Narrow-spectrum antibiotics are as effective as broad-spectrum antibiotics in the treatment of community-acquired pneumonia. Arch Dis Child Educ Pract Ed. 2015;100(4):223.
60. Queen MA et al. Comparative effectiveness of empiric antibiotics for community-acquired pneumonia. Pediatrics. 2014;133(1):e23–9. This multicenter, retrospective study found that narrow-spectrum antibiotic use for children hospitalized with CAP resulted in similar outcomes to broad-spectrum antibiotic use. This study provides supporting evidence for the national guideline’s recommendation to use narrow-spectrum antibiotics as first-line therapy for children hospitalized with CAP.
61. Amarilyo G et al. IV Penicillin G is as effective as IV cefuroxime in treating community-acquired pneumonia in children. Am J Ther. 2014;21(2):81–4.
62. Breuer O et al. Antibiotic treatment for children hospitalized with community-acquired pneumonia after oral therapy. Pediatr Pulmonol. 2015;50(5):495–502.
63. Biondi E et al. Treatment of mycoplasma pneumonia: a systematic review. Pediatrics. 2014;133(6):1081–90.
64. Gardiner SJ, Gavranich JB, Chang AB. Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children. Cochrane Database Syst Rev. 2015;1, CD004875.
65. Ambroggio L, et al. Comparative effectiveness of beta-lactam vs. macrolide monotherapy in children with pneumonia diagnosed in the outpatient setting. Pediatr Infect Dis J. 2015; 839–42.
66. Leyenaar JK et al. Comparative effectiveness of ceftriaxone in combination with a macrolide compared with ceftriaxone alone for pediatric patients hospitalized with community-acquired pneumonia. Pediatr Infect Dis J. 2014;33(4):387–92.
67. Zhanel GG et al. Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant Streptococcus pneumoniae: analysis of phase 3 clinical trial data. J Antimicrob Chemother. 2014;69(10):2835–40.
68. Adam HJ et al. Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997–2006. Int J Antimicrob Agents. 2009;34(1):82–5.
69. Deshpande A et al. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother. 2013;68(9):1951–61.
70. Bradley JS et al. The use of systemic and topical fluoroquinolones. Pediatrics. 2011;128(4):e1034–45.
71. Bradley JS et al. Assessment of musculoskeletal toxicity 5 years after therapy with levofloxacin. Pediatrics. 2014;134(1):e146–53.
72. You SY et al. Effects of methylprednisolone pulse therapy on refractory Mycoplasma pneumoniae pneumonia in children. Allergy Asthma Immunol Res. 2014;6(1):22–6.
73. Izumikawa K et al. Clinical features, risk factors and treatment of fulminant Mycoplasma pneumoniae pneumonia: a review of the Japanese literature. J Infect Chemother. 2014;20(3):181–5.
74. Lavi E et al. Systemic steroid treatment for severe expanding pneumococcal pneumonia. Case Rep Pediatr. 2015;2015:186302.
75. Greenberg D et al. Short-course antibiotic treatment for community-acquired alveolar pneumonia in ambulatory children: a double-blind, randomized, placebo-controlled trial. Pediatr Infect Dis J. 2014;33(2):136–42.
76. Lassi ZS et al. Systematic review on antibiotic therapy for pneumonia in children between 2 and 59 months of age. Arch Dis Child. 2014;99(7):687–93.
77. Lassi ZS, Imdad A, Bhutta ZA. Short-course versus long-course intravenous therapy with the same antibiotic for severe community-acquired pneumonia in children aged two months to 59 months. Cochrane Database Syst Rev. 2015;6, CD008032.
78. Leyenaar JK et al. Variation in resource utilization for the management of uncomplicated community-acquired pneumonia across community and children’s hospitals. J Pediatr. 2014;165(3):585–91.
79. Saleh EA, et al. Guideline-concordant antibiotic prescribing for pediatric outpatients with otitis media, community-acquired pneumonia, and skin and soft tissue infections in a large multispecialty healthcare system. Clin Res Infect Dis. 2015. 2(1).
80. Salih KE et al. Poor adherence to the world health organization guidelines of treatment of severe pneumonia in children at Khartoum. Sudan BMC Res Notes. 2014;7:531.
81. Elemraid MA et al. Changing clinical practice: management of paediatric community-acquired pneumonia. J Eval Clin Pract. 2014;20(1):94–9.
82. Thomson J et al. Hospital outcomes associated with guideline-recommended antibiotic therapy for pediatric pneumonia. J Hosp Med. 2015;10(1):13–8.
83. Agweyu A et al. Prevalence and correlates of treatment failure among Kenyan children hospitalised with severe community-acquired pneumonia: a prospective study of the clinical effectiveness of WHO pneumonia case management guidelines. Trop Med Int Health. 2014;19(11):1310–20.
84. Ross RK et al. Impact of Infectious Diseases Society of America/Pediatric Infectious Diseases Society Guidelines on treatment of community-acquired pneumonia in hospitalized children. Clin Infect Dis. 2014;58(6):834–8.
85. Williams DJ et al. Antibiotic choice for children hospitalized with pneumonia and adherence to national guidelines. Pediatrics. 2015;136(1):44–52.
86. Murtagh Kurowski E et al. Improvement methodology increases guideline recommended blood cultures in children with pneumonia. Pediatrics. 2015;135(4):e1052–9.
87. Wallihan R, Ramilo O. Community-acquired pneumonia in children: current challenges and future directions. J Infect. 2014;69 Suppl 1:S87–90.
88. Rosati P, et al. Are parents of children hospitalized with severe community-acquired pneumonia more satisfied with care when physicians allow them to share decisions on the antibiotic route? Health Expect. 2014.
89. Ferrero F et al. Effectiveness and safety of a clinical decision rule for guiding the management of children with pneumonia vaccinated against pneumococcal disease: a controlled clinical trial. Arch Argent Pediatr. 2015;113(5):397–403.